Overview

ACT-293987 in Pulmonary Arterial Hypertension

Status:
Active, not recruiting

Trial end date:
2023-10-31

Target enrollment:

Participant gender:

Summary

Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)

Phase:

Phase 3

Details

Lead Sponsor:

Actelion

Treatments:

Selexipag